Aspirin and CV events in PAD patients
This article was originally published in The Tan Sheet
Executive Summary
A meta-analysis concludes aspirin treatment provides a significant reduction in nonfatal stroke in patients with peripheral artery disease, but a statistically nonsignificant decrease in cardiovascular events compared to placebo. According to a study in the Journal of the American Medical Association May 13, "additional randomized controlled trials of aspirin therapy are needed to establish the net benefit and bleeding risks in PAD." The researchers, led by Jeffrey Berger of the University of Pennsylvania, synthesized data from 5,269 participants but say the meta-analysis is limited because many of the trials studied were small and of short duration
|
A meta-analysis concludes aspirin treatment provides a significant reduction in nonfatal stroke in patients with peripheral artery disease, but a statistically nonsignificant decrease in cardiovascular events compared to placebo. According to a study in the Journal of the American Medical Association May 13, "additional randomized controlled trials of aspirin therapy are needed to establish the net benefit and bleeding risks in PAD." The researchers, led by Jeffrey Berger of the University of Pennsylvania, synthesized data from 5,269 participants but say the meta-analysis is limited because many of the trials studied were small and of short duration. |